Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108660 · ClinicalTrials.gov registry record · NA
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
A NA study of Central Line Associated Blood Stream Infections (CLABSI), sponsored by Swedish Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 17,800
- Enrollment target
- 19
- Study locations
NCT07108660: Recruiting NA study of Central Line Associated Blood Stream Infections (CLABSI), sponsored by Swedish Medical Center.
NCT07108660 is a NA study of Central Line Associated Blood Stream Infections (CLABSI) that is actively recruiting participants, run by Swedish Medical Center. The registered enrollment target is 17,800 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1169% higher). The trial reports 19 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07108660, a NA study of Central Line Associated Blood Stream Infections (CLABSI), is actively recruiting participants, sponsored by Swedish Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 17,800 participants
- Enrollment target
- 19
- Study locations
Study Summary
Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Associated Blood Stream Infection (CLABSI) Machine Learning (ML) prediction model. The objective is to determine whether providing this model to Infection Preventionists will decrease the CLABSI rates versus routine clinical practice.
Primary Outcome
Rate of CLABSIs (CLABSI Event Per Central Line Days)
Conditions Studied
Interventions
- BEHAVIORAL Infection Preventionist Led Best Practices Reminders
Study Locations (19)
California
- St. Mary Medical Center - Apple Valley
- Providence Saint Joseph Medical Center - Burbank
- St. Jude Medical Center - Fullerton
- Providence Holy Cross Medical Center - Mission Hills
- Mission Hospital - Mission Viejo
- Queen of the Valley Medical Center - Napa
- St. Joseph Hospital - Orange
- Santa Rosa Memorial Hospital - Santa Rosa
- Providence Cedars-Sinai Tarzana Medical Center - Tarzana
Washington
- Swedish Medical Center Edmonds - Edmonds
- Providence Regional Medical Center Everett - Everett
- Providence St. Peter Hospital - Olympia
- Kadlec Regional Medical Center - Richland
- Swedish Medical Center Cherry Hill - Seattle
- Swedish Medical Center First Hill - Seattle
- Providence Sacred Heart Medical Center - Spokane
Alaska
- Providence Alaska Medical Center - Anchorage
Oregon
- Providence St. Vincent Medical Center - Portland
Texas
- Covenant Medical Center - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,800 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT07108660 shows while recruiting
NCT07108660 is an interventional study that assigns participants to a tested intervention. Its 17,800 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1169% higher).
The record links to 1 condition, with Central Line Associated Blood Stream Infections (CLABSI) appearing as the primary indexed condition, and to 1 intervention - of which Infection Preventionist Led Best Practices Reminders is the first listed.
NCT07108660 lists 19 locations in 5 states (California, Washington, Alaska).
Frequently Asked Questions
What is clinical trial NCT07108660 about?
NCT07108660 is a clinical study titled "Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction". Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Asso...
What is the current status of trial NCT07108660?
This trial is currently recruiting. It is a NA study. The enrollment target is 17,800 participants. The study started on 2025-07-01. Estimated completion is 2027-12.
What conditions does trial NCT07108660 study?
This clinical trial studies the following conditions: Central Line Associated Blood Stream Infections (CLABSI).
What interventions are being tested in trial NCT07108660?
The interventions under investigation include: Infection Preventionist Led Best Practices Reminders (BEHAVIORAL).
Who is sponsoring clinical trial NCT07108660?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07108660 being conducted?
This trial has 19 study locations across Alaska, California, Oregon, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Line Associated Blood Stream Infections (CLABSI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07108660's enrollment target sits among peer trials
17,800 11th of 2000 higher than 1,990 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
- NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
- NCT07290361 · 17,587 participants · NA
Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI